UroGen Pharma to be Acquired by Foundry Acquisition
Ticker: URGN · Form: 8-K · Filed: 2024-08-15T00:00:00.000Z
Sentiment: neutral
Topics: acquisition, merger
TL;DR
UroGen Pharma is being bought out by Foundry Acquisition, deal expected to close Q4 2024.
AI Summary
UroGen Pharma Ltd. announced on August 14, 2024, that it has entered into a definitive agreement to be acquired by Foundry Acquisition, Inc. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. UroGen Pharma Ltd. is incorporated in Israel and its principal executive offices are located in Princeton, New Jersey.
Why It Matters
This acquisition by Foundry Acquisition, Inc. signifies a significant change in ownership for UroGen Pharma Ltd., potentially impacting its future strategic direction and operations.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- Foundry Acquisition, Inc. (company) — Acquiring entity
- August 14, 2024 (date) — Date of report
- Fourth quarter of 2024 (date) — Expected closing period
- Israel (location) — Jurisdiction of incorporation
- Princeton, New Jersey (location) — Principal executive offices
FAQ
What is the nature of this 8-K filing?
This is a Current Report filed by UroGen Pharma Ltd. pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on other events.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 14, 2024.
What is UroGen Pharma Ltd.'s state of incorporation?
UroGen Pharma Ltd. is incorporated in Israel.
Where are UroGen Pharma Ltd.'s principal executive offices located?
UroGen Pharma Ltd.'s principal executive offices are located at 400 Alexander Park Drive, 4th Floor, Princeton, New Jersey, 08540.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is +1 (646) 768-9780.
Filing Stats: 379 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2024-08-15 08:00:29
Filing Documents
- d834673d8k.htm (8-K) — 22KB
- 0001193125-24-200993.txt ( ) — 140KB
- urgn-20240814.xsd (EX-101.SCH) — 3KB
- urgn-20240814_lab.xml (EX-101.LAB) — 18KB
- urgn-20240814_pre.xml (EX-101.PRE) — 11KB
- d834673d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 15, 2024 UROGEN PHARMA LTD. By: /s/ Don Kim Don Kim Chief Financial Officer